Diane Christina Galistan

Singapore

Last active 4 months ago

LinkedIn Website
  • Work samples
    6
  • Completed briefs
    56
  • Acceptable rate for a 500-word story
    US$300 - US$500
About
Strong background in healthcare communications, content strategy, and digital marketing. As content lead at Oncoshot, I led content strategies and enhanced brand visibility, Outside of work, I practice BJJ, coach a women’s team, and occasionally direct BJJ tournaments. Currently working on rebranding Impact MMA while organising the next ADCC tournament. In my free time, I take my two cats and pigeon for walks.
Languages
English Mandarin
Expertise
feature image
www.prnewswire.com Press release

GeneASIC Technologies to Exhibit New Genome Data Analysis System at CES 2022

GeneASIC Technologies will be walking into this year's CES 2022 arm in arm with its first product, the GeneASIC Next-Generation Sequencing Analysis Acceleration Platform (NGSAAP). The annual event deemed the most influential tech event and is a showcase of the latest innovation in design and engineering in the consumer technology segment.

Diane Christina Galistan

Available for work

feature image
www.prnewswire.com Press release

Novel Herbal Drug by Xantho Biotechnology Seeks To Be New First-Line Atopic dermatitis Treatment

Botanical drug company Xantho Biotechnology has announced that its atopic dermatitis (AD) treatment, GM-XANTHO, has advanced to phase II of clinical trials. This comes after years of rigorous pre-clinical pharmacology, pharmacokinetics, and toxicity testing. The outcome is a product effective in treating AD that keeps side effects to a minimum.

Diane Christina Galistan

Available for work

feature image
www.bloomberg.com Press release

RemeGen Reiterates Commitment to Its Battle Against Autoimmune Disease on World Strengthened Immunity Day 2021

To celebrate World Strengthened Immunity Day, RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, reiterated its commitment to discovering, developing, and producing best-in-class biological drugs for autoimmune diseases, to create clinical value, and meet the major unmet clinical needs of the world.

Diane Christina Galistan

Available for work

feature image
www.bloomberg.com Press release

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer

RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-drug conjugate (ADC), Disitamab Vedotin (RC48) for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List (NRDL).

Diane Christina Galistan

Available for work